XML 21 R6.htm IDEA: XBRL DOCUMENT v3.25.2
CONSOLIDATED STATEMENTS OF STOCKHOLDERS' DEFICIT - USD ($)
$ in Thousands
Total
Redeemable Preferred Stock
Series A-1 Convertible Preferred Stock
Series B Convertible Preferred Stock
Common Stock
Common Stock
Series A-1 Convertible Preferred Stock
Common Stock
Series B Convertible Preferred Stock
Additional Paid-in Capital
Additional Paid-in Capital
Series A-1 Convertible Preferred Stock
Additional Paid-in Capital
Series B Convertible Preferred Stock
Accumulated Other Comprehensive Loss
Accumulated Deficit
Beginning Balance at Dec. 31, 2022 $ (32,314)       $ 1     $ 99,877       $ (132,192)
Beginning Balance (in shares) at Dec. 31, 2022         1,083,196              
Exercise of stock options 145             145        
Exercise of stock options, (in shares)         11,943              
Stock-based compensation expense 8,357             8,357        
Issuance of convertible preferred stock for the exercise of warrant     $ 6 $ 89         $ 6 $ 89    
Issuance of convertible preferred stock for the exercise of warrant (in shares)           20 342          
Reverse recapitalization, net of transaction costs 58,573       $ 1     58,572        
Reverse recapitalization, net of transaction costs (in shares)         549,435              
Recognition of warrant liabilities in connection with the Merger (13,762)             (13,762)        
Issuance of common stock in connection with vesting of RSU awards (in shares)         36,737              
Issuance of common stock for the conversion of convertible notes 25,570             25,570        
Issuance of common stock for the conversion of convertible notes (in shares)         132,049              
Recognition of earn-out liabilities (53,040)             (53,040)        
Reclassification of Legacy Allurion liabilitiy classified warrants to equity classification 929             929        
Derecognition of liabilities associated with the Backstop Shares, Hunter shares, and the additional RTW and Fortress shares and issuance of related shares 16,098             16,098        
Derecognition of liabilities associated with the Backstop Shares, Hunter shares, and the additional RTW and Fortress shares and issuance of related shares (in shares)         91,508              
Issuance of common stock for the exercise of warrants 46             46        
Issuance of common stock for the exercise of warrants (in shares)         878              
Issuance of common stock for commitment shares for equity line financing 123             123        
Issuance of common stock for commitment shares for equity line financing (in shares)         1,421              
Other comprehensive income (loss) (Restated) 700                   $ 700  
Net income (loss) (Restated) (82,817)                     (82,817)
Ending Balance at Dec. 31, 2023 (71,297)       $ 2     143,010     700 (215,009)
Ending Balance (in shares) at Dec. 31, 2023         1,907,529              
Exercise of stock options 9             9        
Exercise of stock options, (in shares)         186              
Stock-based compensation expense 552             552        
Issuance of common stock in connection with vesting of RSU awards (in shares)         2,505              
Issuance of common stock for the exercise of warrants (in shares)         6              
Stock issued during period value 378             378        
Stock isssued during the period (in shares)         5,730              
Other comprehensive income (loss) (Restated) 2,200                   2,200  
Net income (loss) (Restated) 1,996                     1,996
Ending Balance at Mar. 31, 2024 (66,162)       $ 2     143,949     2,900 (213,013)
Ending Balance (in shares) at Mar. 31, 2024         1,915,956              
Beginning Balance at Dec. 31, 2023 (71,297)       $ 2     143,010     700 (215,009)
Beginning Balance (in shares) at Dec. 31, 2023         1,907,529              
Net income (loss) (Restated) (6,326)                      
Ending Balance at Jun. 30, 2024 (70,582)       $ 2     144,771     5,980 (221,335)
Ending Balance (in shares) at Jun. 30, 2024         1,918,927              
Beginning Balance at Dec. 31, 2023 (71,297)       $ 2     143,010     700 (215,009)
Beginning Balance (in shares) at Dec. 31, 2023         1,907,529              
Net income (loss) (Restated) 2,410                      
Ending Balance at Sep. 30, 2024 $ (64,790)       $ 3     150,696     (2,890) (212,599)
Ending Balance (in shares) at Sep. 30, 2024         2,574,783              
Temporary Equity, Balance (in Shares) at Sep. 30, 2024 2,260,159 2,260,159                    
Beginning Balance at Dec. 31, 2023 $ (71,297)       $ 2     143,010     700 (215,009)
Beginning Balance (in shares) at Dec. 31, 2023         1,907,529              
Exercise of stock options 25             25        
Exercise of stock options, (in shares)         649              
Stock-based compensation expense 3,056             3,056        
Issuance of common stock in connection with vesting of RSU awards (in shares)         13,040              
Issuance of preferred stock in connection with Private Placement, net of issuance costs (in shares)   2,260,159                    
Issuance of preferred stock in connection with Private Placement, net of issuance costs   $ 979                    
Issuance of common stock for the exercise of warrants 1             1        
Issuance of common stock for the exercise of warrants (in shares)         13              
Stock issued during period value 1,007             1,007        
Stock isssued during the period (in shares)         75,618              
Exercise of PIPE Conversion Option (547)             (547)        
Exercise of PIPE Conversion Option (in shares)         (30,000)              
Issuance of shares common stock in connection with public offering, net of issuance costs ( in shares)         653,351              
Issuance of value common stock in connection with public offering, net of issuance costs 5,066       $ 1     5,065        
Issuance of value common stock for conversion of preferred stock 979 $ (979)           979        
Issuance of shares common stock for conversion of preferred stock ( in shares)   (2,260,159)     90,407              
Other comprehensive income (loss) (Restated) (9,070)                   (9,070)  
Net income (loss) (Restated) (7,198)                     (7,198)
Ending Balance at Dec. 31, 2024 (77,978)       $ 3     152,596     (8,370) (222,207)
Ending Balance (in shares) at Dec. 31, 2024         2,710,607              
Beginning Balance at Mar. 31, 2024 (66,162)       $ 2     143,949     2,900 (213,013)
Beginning Balance (in shares) at Mar. 31, 2024         1,915,956              
Exercise of stock options 16             16        
Exercise of stock options, (in shares)         460              
Stock-based compensation expense 805             805        
Issuance of common stock in connection with vesting of RSU awards (in shares)         2,505              
Issuance of common stock for the exercise of warrants (in shares)         6              
Other comprehensive income (loss) (Restated) 3,080                   3,080  
Net income (loss) (Restated) (8,322)                     (8,322)
Ending Balance at Jun. 30, 2024 (70,582)       $ 2     144,771     5,980 (221,335)
Ending Balance (in shares) at Jun. 30, 2024         1,918,927              
Stock-based compensation expense 860             860        
Issuance of common stock in connection with vesting of RSU awards (in shares)         2,505              
Issuance of preferred stock in connection with Private Placement, net of issuance costs (in shares)   2,260,159                    
Issuance of preferred stock in connection with Private Placement, net of issuance costs   $ 979                    
Issuance of shares common stock in connection with public offering, net of issuance costs ( in shares)         653,351              
Issuance of value common stock in connection with public offering, net of issuance costs 5,066       $ 1     5,065        
Other comprehensive income (loss) (Restated) (8,870)                   (8,870)  
Net income (loss) (Restated) 8,736                     8,736
Ending Balance at Sep. 30, 2024 $ (64,790)       $ 3     $ 150,696     $ (2,890) $ (212,599)
Ending Balance (in shares) at Sep. 30, 2024         2,574,783              
Temporary Equity, Balance (in Shares) at Sep. 30, 2024 2,260,159 2,260,159